NovoCure COO Sells Over 43,000 Shares

Mukund Paravasthu reduces stake in medical device company by over 37%

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

NovoCure Limited (NASDAQ:NVCR) Chief Operating Officer Mukund Paravasthu sold 43,246 shares of the company's stock on March 5th, 2026. The shares were sold at an average price of $13.77, resulting in a total transaction value of $595,497.42. Following the sale, Paravasthu's direct ownership in the company decreased by 37.26% to 72,832 shares, valued at approximately $1,002,896.64.

Why it matters

This transaction represents a significant reduction in the COO's stake in NovoCure, a medical device company that develops a novel cancer treatment technology called Tumor Treating Fields. Insider transactions can provide insights into management's confidence in the company's outlook and future performance.

The details

Paravasthu's sale of over 43,000 shares comes just a day after he sold an additional 5,377 shares on March 4th. The transactions were disclosed in a filing with the Securities and Exchange Commission. NovoCure's stock price has fluctuated between $9.82 and $21.55 over the past 12 months.

  • The share sale transactions occurred on March 4th and March 5th, 2026.
  • NovoCure's stock price closed at $14.23 on the day of the larger 43,246 share sale.

The players

Mukund Paravasthu

The Chief Operating Officer of NovoCure Limited, a medical device company that develops a novel cancer treatment technology called Tumor Treating Fields.

NovoCure Limited

A global oncology company that pioneered Tumor Treating Fields (TTFields), a non-invasive therapy for solid tumors. The company is headquartered in Haifa, Israel and has a second operational center in Portsmouth, New Hampshire.

Got photos? Submit your photos here. ›

The takeaway

The significant reduction in the NovoCure COO's stake could signal a shift in management's outlook or plans for the company. Investors will likely monitor any further insider transactions and the company's financial performance to assess the implications of this sale.